John Latham - Alder Biopharmaceutica Insider

Alder Biopharmaceuticals Inc -- USA Stock  

USD 13.60  0.30  2.16%

Co-Founder and Chief Scientific Officer

Dr. John A. Latham, Ph.D., is Chief Scientific Officer of the Company. Dr. Latham served as a director, senior director, and most recently as Vice President of Gene Function and Target Validation for Celltech Group plc. In 1994, Dr. Latham joined Darwin Molecular Corporationrationration, a firstgeneration genetodrug biotechnology company, as a founding director, where he served from 1994 to 1998. Dr. Latham was one of the early scientists hired by Gilead Sciences, Inc., a biopharmaceutical company, and, from 1989 to 1994, he was a member of a core group established to exploit novel oligonucleotidebased technologies
Age: 56    Ph.D    
Latham holds a Ph.D. in Biochemistry from Massachusetts Institute of Technology and a B.S. in Chemistry from Colorado State University.

John Latham Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (51.07) % which means that it has lost $51.07 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (87.27) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington. Alder Biopharmaceutica operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 193 people.Alder Biopharmaceuticals Inc (ALDR) is traded on NASDAQ General Markets in USA. It is located in WASHINGTON, U.S.A and employs 193 people. Alder Biopharmaceutica is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Equity Analysis Now

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Hide  View All  NextLaunch Equity Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Alder Biopharmaceuticals Inc to your portfolio

Top Management

Alder Biopharmaceutica Leadership Team
Xavier GallotLavallee, Executive
Deepa Pakianathan, Director, MBA
Bruce Montgomery, Director
Anne TrotouxCoppermann, Executive
Christian Viguie, Chairman
Deepika Pakianathan, Director, MBA
John Latham, Founder, Ph.D
Bruno Pavlovsky, Executive
Wendy Yarno, Director, MBA
Joel Desmaris, Executive
Olivier Lambert, Executive
Randal Hassler, President
Paul Carter, Director
Stephen Dow, Chairman, MBA
Randall Schatzman, CEO, Ph.D
Mark Litton, Executive, MBA
Larry Benedict, SVP
Pierre Conte, Executive
Pierre Tourrette, Chairman
Heather Preston, Director
Jeffrey Smith, President
Timothy Whitaker, Executive
James Bucher, President
Paul Cleveland, Director
Clay Siegall, Director, Ph.D
Frederic Serre, Chairman
Elisabeth Sandoval, Executive, MBA
Philippe Mattia, Executive

Stock Performance

Alder Biopharmaceutica Performance Indicators